HCW Biologics Inc Total Assets
HCW Biologics Inc total assets. Based on the latest financial reports, HCW Biologics Inc (HCWB) holds total assets worth $26.77 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is HCW Biologics Inc worth for the company's overall valuation and market capitalisation.
Total Assets of HCW Biologics Inc (2019–2025)
Total assets of HCW Biologics Inc from 2019 to 2025. This chart illustrates how HCW Biologics Inc's total assets have evolved over time, based on quarterly financial data. See HCWB stock price and chart for real-time trading data and today's change.
HCW Biologics Inc - Asset Composition Analysis
HCW Biologics Inc Total Assets Breakdown (December 2025)
HCW Biologics Inc total assets breakdown as of December 2025. HCW Biologics Inc's total assets of $26.77 Million consist of 9.3% current assets and 90.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.0% |
| Accounts Receivable | $32.17K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of HCW Biologics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HCW Biologics Inc's current assets represent 9.3% of total assets in 2025, a decrease from 79.8% in 2019.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2025, down from 73.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
HCW Biologics Inc Competitors by Total Assets
Key competitors of HCW Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
HCW Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.11 | 18.19 |
| Quick Ratio | 0.06 | 0.11 | 17.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-17.51 Million | $-23.95 Million | $41.16 Million |
HCW Biologics Inc - Advanced Valuation Insights
This section examines the relationship between HCW Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.73 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -18.9% |
| Total Assets | $24.52 Million |
| Market Capitalization | $2.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values HCW Biologics Inc's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: HCW Biologics Inc's assets decreased by 18.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HCW Biologics Inc (2019–2025)
The table below shows the annual total assets of HCW Biologics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.52 Million | -18.91% |
| 2024-12-31 | $30.24 Million | +6.04% |
| 2023-12-31 | $28.51 Million | -39.09% |
| 2022-12-31 | $46.81 Million | -12.53% |
| 2021-12-31 | $53.51 Million | +247.54% |
| 2020-12-31 | $15.40 Million | +52.97% |
| 2019-12-31 | $10.07 Million | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more